Tesamorelin vs Sermorelin: Two GHRH Analogues Compared

Both are GHRH, cut to different lengths

Tesamorelin and sermorelin are both synthetic versions of growth hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to release growth hormone. The difference between them starts with how much of the natural 44 amino acid hormone each one keeps.

Sermorelin is the first 29 amino acids, unmodified. That fragment carries the hormone's full biological activity on its own, but with no protection from the enzymes that break peptides down, so it clears from the blood within minutes.

Tesamorelin keeps all 44 amino acids and adds a hexenoyl group on the first one, a tyrosine, that resists that breakdown. Even so, its label still reports a short half-life, 8 to 38 minutes depending on the formulation and population, because the effect it produces is a daily pulse rather than a sustained level.

Regulatory status is the sharpest difference

This is where the two compounds' stories split.

Sermorelin was once an approved medicine. Serono sold it as Geref for pituitary function testing and paediatric growth hormone deficiency. It left the US market in 2008, a withdrawal tied to manufacturing rather than a safety or efficacy finding, and it has not returned as a branded product since. Tesamorelin, by contrast, is a current, actively marketed prescription drug: the US FDA approved it in 2010 as Egrifta, and newer formulations followed, including Egrifta WR in March 2025.

What each one's trial evidence actually covers

The two compounds were tested in different populations for different reasons, so their evidence is not directly comparable.

Tesamorelin's pivotal trial, published in the New England Journal of Medicine in 2007, randomised 412 adults with HIV and abdominal fat accumulation to 2 mg daily or placebo for 26 weeks. Visceral fat, measured by CT scan, fell 15.2% on tesamorelin and rose 5.0% on placebo. IGF-1 rose 81%. A separate 2019 trial in 61 adults with HIV and fatty liver disease found liver fat fraction fell by an absolute 4.1% more than placebo over 12 months. Both are real Phase 3 and controlled-trial-grade data in a specific clinical population.

Sermorelin's human evidence is older and smaller. A 1997 study gave healthy men aged 64 to 76 a nightly injection for six weeks and found GH secretion and IGF-1 rose, confirming the ageing pituitary still responds to GHRH. A companion study using a closely related GHRH(1-29) analogue ran 16 weeks in adults aged 55 to 71 and reported IGF-1 rises in both sexes, with lean mass gains and improved insulin sensitivity in men. These were exploratory ageing studies, not trials built around a specific disease outcome, and none measured hard endpoints such as fractures or survival.

Neither compound has been tested against the other in a head-to-head trial, so any claim that one "works better" than the other is not something the literature actually answers. It is also worth noting that "better" would mean different things for each: tesamorelin's trials were built around a defined clinical endpoint, visceral fat by CT scan, in a population with a specific medical condition, while sermorelin's ageing studies looked at broader markers of the GH axis in otherwise healthy older adults. Comparing their reported numbers side by side risks treating two different research questions as if they were one.

Side effects reported

The tesamorelin FDA label lists joint pain, injection-site redness and itching, limb pain, leg and foot swelling, and muscle pain as the most common adverse reactions, each above 5% of patients, along with warnings on IGF-1 elevation, fluid retention and glucose intolerance. The sermorelin-era ageing literature reports injection-site reactions, facial flushing, headache and occasional dizziness as the most common events, with the same theoretical long-term IGF-1 concerns that apply to any GH-raising compound. Full detail is on the side effect management guide.

How the two fit next to other GHRH analogues

Both sit alongside CJC-1295 and CJC-1295 with DAC, later attempts to extend GHRH's short half-life using different chemistry, and alongside ghrelin-receptor peptides such as ipamorelin, which work through a separate pathway and are sometimes studied together with a GHRH analogue. Tesamorelin is the only one of this whole group with a current drug approval; the rest, sermorelin included, are research compounds without one.

Status in the Philippines

Neither tesamorelin nor sermorelin has an identified FDA Philippines registration. Tesamorelin is an approved medicine in the United States, so where it is used, prescribing belongs with a licensed Philippine physician. Sermorelin is not currently an approved medicine anywhere, and both compounds circulate locally through research-chemical suppliers rather than through pharmacies. Because both raise IGF-1 through the same pathway, glucose and IGF-1 are the labs the trial literature points to for either one; see bloodwork in the Philippines.

Cost is part of why the two names get searched together locally. Tesamorelin as an approved medicine abroad carries pharmaceutical pricing wherever it is dispensed legitimately, while sermorelin and the other GHRH analogues circulate here only as unregistered research material. Neither route changes the underlying evidence gap between a Phase 3-tested, narrowly approved drug and a set of compounds without that approval.

Storage

Tesamorelin's current US label stores the vial at room temperature, 20 to 25°C, protected from light, with the mixed solution discarded after seven days, though Philippine room temperature often runs warmer than that range. Sermorelin, like most lyophilised research peptides, is best kept refrigerated before mixing and at 2 to 8°C afterward. Brownouts, common in much of the country, can push a household fridge out of range within hours, so both are worth planning storage around rather than assuming a fridge holds steady.